-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JrfbmrwHk1zZW+ZAg2L50Ec5pr2tgoYYISGkqbVgx6X8zWDurrBYEkXvAM55M7++ ZcwAn5rDc5PB+Q7pTrCJhg== 0001104659-07-053426.txt : 20070711 0001104659-07-053426.hdr.sgml : 20070711 20070711202321 ACCESSION NUMBER: 0001104659-07-053426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070710 FILED AS OF DATE: 20070711 DATE AS OF CHANGE: 20070711 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOENVISION INC CENTRAL INDEX KEY: 0001028205 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113375915 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE STREET 2: 41ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 212-750-6700 MAIL ADDRESS: STREET 1: 345 PARK AVENUE STREET 2: 41ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: ASCOT GROUP INC DATE OF NAME CHANGE: 19961205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wichita Bio CORP CENTRAL INDEX KEY: 0001402396 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31787 FILM NUMBER: 07975140 BUSINESS ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02042 BUSINESS PHONE: 617-252-7500 MAIL ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02042 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31787 FILM NUMBER: 07975141 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQ CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 a4.xml 4 X0202 4 2007-07-10 0 0001028205 BIOENVISION INC BIVN 0000732485 GENZYME CORP C/O GENZYME CORPORATION 500 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001402396 Wichita Bio CORP C/O GENZYME CORPORATION 500 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2007-07-10 4 P 0 8706644 5.60 A 8706644 D Series A Convertible Participating Preferred Stock 2007-07-10 4 P 0 2250000 11.23 A Common Stock 2250000 D Includes 123,114 shares of Common Stock (hereinafter defined) tendered by notice of guaranteed delivery in conjunction with a tender offer by Wichita Bio Corporation ("Wichita Bio") for (i) all of the issued and outstanding common stock, $0.001 par value per share (the "Common Stock") of Bioenvision, Inc. ("Bioenvision") including all rights to purchase Series A Junior Participating Preferred Stock and (ii) all of the issued and outstanding shares of Series A Convertible Participating Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock") of Bioenvision. Shares of Series A Preferred Stock are convertible into Common Stock from the date of issuance, May 8, 2002, and any time thereafter. The conversion price of Series A Preferred Stock is equal to $1.50 per share of Common Stock, subject to adjustment upon the occurrence of certain events set forth in the Certificate of Designations for the Series A Preferred Stock. The number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock will be such number equal to the quotient obtained from dividing the then applicable liquidation amount of the share of Series A Preferred Stock by the then applicable conversion price as set forth in the Certificate of Designations for the Series A Preferred Stock. On July 10, 2007, the 2,250,000 shares of Series A Preferred Stock were convertible into 4,500,000 shares of Common Stock. The price paid for each share of Series A Preferred Stock equals $11.20 plus the accrued but unpaid dividends up to, and including, July 10, 2007 (approximately $0.03 per share). /s/ Peter Wirth, Chief Legal Officer & Executive Vice President 2007-07-10 /s/ Peter Wirth, Secretary & Vice President 2007-07-10 -----END PRIVACY-ENHANCED MESSAGE-----